Skip to main content
Swing Capital

Beta Drugs Ltd

NSE: BETA

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

₹1,180
52W: ₹990 — ₹2000
PE 83.4 · Book ₹148 · +697% vs book
Market Cap₹1,196 Cr
Stock P/E83.4Price to Earnings
ROCE11.2%Return on Capital
ROE10.3%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company's median sales growth is 21.5% of last 10 years

Weaknesses

  • −Stock is trading at 8.12 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Earnings include an other income of Rs.11.1 Cr.

Shareholding Pattern

Promoters64.63%
FIIs1.16%
DIIs2.15%
Public32.06%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters66.73%66.73%66.73%66.73%66.73%66.73%64.9%▼1.864.63%▼0.3
FIIs0.9%1.16%▲0.31.15%▼0.00.9%▼0.20.9%0.9%1.14%▲0.21.16%▲0.0
DIIs0.12%0.16%▲0.00.17%▲0.00.17%0.26%▲0.10.29%▲0.01.9%▲1.62.15%▲0.3
Public32.25%31.95%▼0.331.95%32.2%▲0.332.11%▼0.132.07%▼0.032.07%32.06%▼0.0

Financial Statements

MetricDec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Sales48.2753.7454.4850.2854.35
Expenses42.5548.4949.7543.7444.6
Operating Profit5.725.254.736.549.75
OPM %11.85%9.77%8.68%13.01%17.94%
Net Profit0.751.391.513.255.33
EPS ₹0.741.381.53.215.26

AI Insights

Revenue Trend

Mar 2026 revenue at ₹225Cr, up 2.3% YoY. OPM at 13%.

Debt Position

Borrowings at ₹130Cr. Debt-to-equity ratio: 0.94x. Moderate leverage.

Institutional Flow

DIIs: 2.15% (+2.11pp change). FIIs: 1.16% (+0.87pp change). Promoters hold 64.63%.

Margin & Efficiency

ROCE improving from -3% (Mar 2015) to 11% (Mar 2026). Working capital days: 74.

Valuation

PE 83.4x with 11.2% ROCE. Price is 697% above book value of ₹148. Dividend yield: 0%.

Recent Announcements